DAVID and GOLIATH - Genoma sued by Illumina. Notice of Patent Infringement Proceedings

Geneva, Switzerland - 22 April 2016 

We, Genoma SA, (DAVID),  Genomics company specialised in Prenatal and Oncology DNA analysis for early detection and follow-up of genetically caused diseases, have read in a press release that Illumina Inc. (GOLIATH) and its wholly-owned subsidiary Verinata Health Inc., have filed a patent infringement suit against us, Genoma SA, in the Federal Patent Court in Switzerland. The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842. 

The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT).

Genoma's Directors hold a firm belief that Tranquility, a cell-free fetal DNA, non-invasive test developed by Genoma for early detection of Down syndrome, as well as other trisomies, like trisomy 13 and trisomy 18, does not infringe the patents as claimed by Illumina.

The Company will update the market in respect of further developments, as appropriate.

 

Genoma is a company of Esperite group.